A Phase 1, Randomized, Double-blind, Placebo-controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Multiple Escalating Oral Doses Of Pf-06865571 In Healthy, Including Overweight And Obese, Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 29 Aug 2017
At a glance
- Drugs PF 06865571 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Sponsors Pfizer
- 18 Aug 2017 Planned End Date changed from 12 Apr 2018 to 10 Apr 2018.
- 18 Aug 2017 Planned primary completion date changed from 12 Apr 2018 to 10 Apr 2018.
- 18 Aug 2017 Status changed from not yet recruiting to recruiting.